Hepatitis C is a silent, life-threatening liver infection that is now remarkably curable.
In short: Most people infected with the hepatitis C virus have no idea they carry it, as symptoms often remain hidden for decades. While it can lead to severe liver damage or cancer, modern medicine has transformed this once-daunting diagnosis into a condition that is curable in over 95% of cases.
The hepatitis C virus (HCV) is a bloodborne pathogen that primarily targets the liver. Transmission occurs through direct blood-to-blood contact, most commonly via shared injection equipment, poorly sterilized medical tools, or unscreened blood transfusions. While it is not spread through casual contact like hugging or sharing food, the virus is highly persistent. Approximately 70% of those initially infected develop a chronic condition, which often progresses without noticeable symptoms for years until significant liver damage, such as cirrhosis or hepatocellular carcinoma, occurs.
Diagnosis is a two-step process: an initial antibody test identifies exposure, followed by a nucleic acid test to confirm active viral RNA. Because acute infections are frequently asymptomatic, early detection is difficult. However, the landscape of treatment shifted dramatically in 2013 and 2014 with the approval of direct-acting antivirals (DAAs). These oral medications, typically taken for 8 to 12 weeks, offer a near-universal cure. This development is considered a milestone in public health, as it allows for the eradication of a severe, chronic disease that previously required less effective, interferon-based therapies.
Despite these medical advancements, the global burden remains significant. Estimates suggest 47 million people live with chronic infection, with hundreds of thousands of deaths annually attributed to liver complications. Access to testing and treatment remains a primary challenge, particularly in regions with high prevalence. While there is currently no vaccine, the combination of harm reduction, widespread screening, and the high efficacy of DAAs provides a clear path to managing and eventually eliminating the disease's impact on global health.
The virus was only proven to exist in 1989, having previously been categorized as non-A, non-B hepatitis. Today, it is recognized as a leading cause of liver transplantation, though the virus can recur even after surgery. Because the infection can be contracted more than once, ongoing prevention—such as using sterile equipment and avoiding shared personal items—is essential even for those who have been successfully cured.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Hepatitis C
- Also: Hepatitis C
- Also: www.nhs.uk — Hepatitis C
- Also: my.clevelandclinic.org — What Is Hepatitis C?
To cite this card, link to https://intellectplus.co.uk/app/health-hepatitis-c.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics